Hematology Ha-Na Kim Favorite Doctor
- SpecialtyMyelodysplastic syndrome, Myeloproliferative neoplasms, Cytopenia, Coagulopathy
- Site
Schedule
| Week | M | T | W | T | F | S |
|---|---|---|---|---|---|---|
| AM | Present | |||||
| PM | Present | Present | Present |
Clinical Interests
Myelodysplastic syndrome (MDS), Myeloproliferative neoplasms (MPN), Anemia, Leukopenia, Thrombocytopenia, Coagulopathy
Education
Career
Community
Training
License
Paper
| 2021 | Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. Ther Adv Med Oncol. 2021 Feb 26:13:1758835921992992. doi: 10.1177/1758835921992992. |
|---|---|
| 2021 | The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. J Cancer Res Clin Oncol. 2022 Sep;148(9):2427-2435. doi:. 10.1007/s00432-021-03781-6. Epub 2021 Sep 12. |
| 2021 | Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach. Cancers (Basel). 2021 Nov 21;13(22):5835. doi: 10.3390/cancers13225835. |
| 2021 | Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer. Cancer. 2021 Jan 1;12(2):460-466. doi: 10.7150/jca.49176. |
| 2021 | When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer. J Cancer. 2021 Jul 25;12(18):5681-5686. doi: 10.7150/jca.62853. |
| 2021 | Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer. Technol Cancer Res Treat. 2021 Jan-Dec:20:15330338211062324. doi: 10.1177/15330338211062324. |
| 2022 | The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. J Cancer Res Clin Oncol. 2022 Sep;148(9):2427-2435. doi:. 10.1007/s00432-021-03781-6. Epub 2021 Sep 12. |
| 2022 | Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder. Investig Clin Urol. 2022 Mar;63(2):168-174. doi: 10.4111/icu.20210407. |
| 2023 | Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Cancer Res Treat. 2023 Oct;55(4):1104-1112. doi: 10.4143/crt.2023.502. |
